EMEA-002861-PIP02-20-M07 - paediatric investigation plan
Tozinameran
Tozinameran / famtozinameran
tozinameran/ riltozinameran
raxtozinameran
PIPHuman
Key facts
- Invented name
- Comirnaty
- Active Substance
- Tozinameran
- Tozinameran / famtozinameran
- tozinameran/ riltozinameran
- raxtozinameran
- Therapeutic area
- Infections and infestations
- Decision number
- P/0105/2024
- PIP number
- EMEA-002861-PIP02-20-M07
- Pharmaceutical form(s)
- Concentrate for dispersion for injection
- Dispersion for injection
- Condition(s) / indication(s)
- Prevention of Coronavirus disease 2019 (COVID-19)
- Route(s) of administration
- Intramuscular use
- Contact for public enquiries
BioNTech Manufacturing GmbH
Tel. +49 613190847507
E-mail: Constanze.Blume.Comirnaty@biontech.de- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date